U.S. tariff agreement sealed over the weekend has been described as a “dark day” for Europe and even a capitulation to American demands.

A tactic of deference and praise, along with a studied attempt to avoid any public blowups, coaxed President Trump into changes on key issues like Gaza and Ukraine.

The fee for Americans and other visa-free travelers won’t begin until fall 2026, but the price is about to triple, officials say, because of rising costs.

A new factory in Hungary will help the Chinese automaker take on auto giants like Volkswagen on their home turf.

Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to higher drug prices.

European shares turned lower on Tuesday after a shock profit warning from Novo Nordisk wiped more than 80 billion euros ($92.34 billion) off the heavyweight drugmaker's market value at one point.

S&P 500 futures moved up 0.27% this morning. But the STOXX Europe 600 rose by more than double that in early trading as investors in Europe realized that the pact seems to contain several advantages for the EU.

LONDON (Reuters) -In the end, Europe found it lacked the leverage to pull Donald Trump's America into a trade pact on its terms and so has signed up to a deal it can just about stomach - albeit one that is clearly skewed in the U.S.'s favour.

European stocks are near record highs again, seemingly shaking off tense trade talks and currency headwinds, while volatility has evaporated, giving rise to four key themes that investors are playing as they wait for the next major catalyst.

UBS forecasts that the current installed global data center capacity of 85 GW will double due to soaring demand. Based on the EU's 20-billion-euro investment and the plan for each factory to run 100,000 advanced processors, UBS estimates each factory could be around 100-150 MW with a total capacity for all of the facilities of around 1.5-2 GW.

The NHS warns that excessive heat is potentially dangerous for children aged five and under, and older people aged 65 years and over, as well as people with underlying health conditions including heart problems, breathing problems, and diabetes.

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through logistics and marketing roles to head of international operations. Now the relatively unknown insider is moving into the spotlight with a daunting task: revive a once high-flying drugmaker from a steep descent that’s wiped out two-thirds of its value in the past year.